Larry H Matherly
Overview
Explore the profile of Larry H Matherly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2785
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taub J, Buck S, Xavier A, Edwards H, Matherly L, Ge Y
Pediatr Blood Cancer
. 2024 Aug;
71(11):e31247.
PMID: 39120434
An attractive flower from the island of Madagascar has in part saved the lives of thousands of children with acute lymphoblastic leukemia (ALL). Random mutations and alterations to the genome...
2.
OConnor C, Schneider M, Katinas J, Nayeen M, Shah K, Magdum T, et al.
Mol Pharmacol
. 2024 Jul;
106(4):173-187.
PMID: 39048308
Folate-dependent one-carbon (C1) metabolism encompasses distinct cytosolic and mitochondrial pathways connected by an interchange among serine, glycine, and formate. In both the cytosol and mitochondria, folates exist as polyglutamates, with...
3.
Chehade H, Gogoi R, Adzibolosu N, Galoforo S, Fehmi R, Kheil M, et al.
Cancer Res Commun
. 2024 Jul;
4(8):2075-2088.
PMID: 39028933
Significance: We show that BRCA1 and BRCA2 mutation statuses differentially impact the regulation of the Wnt/β-catenin signaling pathway, a major effector of cancer initiation and progression. Our findings provide a...
4.
Wallace-Povirk A, OConnor C, Dekhne A, Bao X, Nayeen M, Schneider M, et al.
Mol Cancer Ther
. 2024 Feb;
23(6):809-822.
PMID: 38377173
One-carbon (C1) metabolism is compartmentalized between the cytosol and mitochondria with the mitochondrial C1 pathway as the major source of glycine and C1 units for cellular biosynthesis. Expression of mitochondrial...
5.
Katinas J, Nayeen M, Schneider M, Shah K, Fifer A, Klapper L, et al.
Biochemistry
. 2024 Feb;
PMID: 38324671
We previously discovered first-in-class multitargeted 5-substituted pyrrolo[3,2-]pyrimidine antifolates that inhibit serine hydroxymethyltransferase 2 (SHMT2), resulting in potent in vitro and in vivo antitumor efficacies. In this report, we present crystallographic...
6.
Kaku K, Ravindra M, Tong N, Choudhary S, Li X, Yu J, et al.
ACS Med Chem Lett
. 2023 Dec;
14(12):1682-1691.
PMID: 38116433
Pemetrexed and related 5-substituted pyrrolo[2,3-]pyrimidine antifolates are substrates for the ubiquitously expressed reduced folate carrier (RFC), and the proton-coupled folate transporter (PCFT) and folate receptors (FRs) which are more tumor-selective....
7.
Hurrish K, Su Y, Patel S, Ramage C, Zhao J, Temby B, et al.
Biochem Pharmacol
. 2023 Dec;
220:115981.
PMID: 38081370
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...
8.
Nayeen M, Katinas J, Magdum T, Shah K, Wong J, OConnor C, et al.
J Med Chem
. 2023 Aug;
66(16):11294-11323.
PMID: 37582241
Multitargeted agents provide tumor selectivity with reduced drug resistance and dose-limiting toxicities. We previously described the multitargeted 6-substituted pyrrolo[3,2-]pyrimidine antifolate with activity against early- and late-stage pancreatic tumors with limited...
9.
Tong N, Wong-Roushar J, Wallace-Povirk A, Shah Y, Nyman M, Katinas J, et al.
ACS Pharmacol Transl Sci
. 2023 May;
6(5):748-770.
PMID: 37200803
Multitargeted agents with tumor selectivity result in reduced drug resistance and dose-limiting toxicities. We report 6-substituted thieno[2,3-]pyrimidine compounds (-) with pyridine (, ), fluorine-substituted pyridine (), phenyl (, ), and...
10.
Hurrish K, Su Y, Patel S, Ramage C, Carter J, Edwards H, et al.
Res Sq
. 2023 May;
PMID: 37162954
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...